secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001193125-24-237582
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics appoints Eric Hyllengren as COO, retains CFO role
-----------------------------------------------------------------------

- Eric Hyllengren appointed Chief Operating Officer effective Oct 14, 2024, while continuing as CFO.
- Salary increased to $520,000 per year in connection with the promotion.
- Hyllengren has been CFO since April 2023 and with Atara since 2018.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524237582/0001193125-24-237582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524237582/d729291d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-237582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer